


BMI at the end of follow-up was 24.7 kg/m² (0.4 kg/m² median annual change), the obesity incidence rate was 37.4 per 1000 person-years and the median time to obesity diagnosis was 1.9 years (vs. 4.7 years of follow-up for participants remaining non-obese). Factors associated with obesity after ART initiation included younger age at ART initiation, female sex, higher baseline BMI, lower baseline CD4⁺ T lymphocyte count, higher baseline HIV-1 RNA, having an integrase inhibitor as the most-used ART core drug and having diagnoses of hypertension and diabetes mellitus (Figure).

Conclusion. Obesity following ART initiation is frequent among HIV+ adults, with rates increasing in recent years. Both traditional (female sex) and HIV-specific (more advanced HIV disease, integrase inhibitor use) risk factors contribute importantly to obesity incidence following ART initiation.

Figure. Factors Associated with Incident Obesity After Multivariate Analysis

	aHR	Lower CI	Upper CI
Age at ART Initiation (per 10 year increase)	0.82	0.72	0.94
Sex: Female (ref male)	1.66	1.26	2.20
Sex: Transgender Women	0.87	0.55	1.36
Baseline Viral Load (copies/mL) Log10	1.16	1.02	1.33
ART Backbone Drug: AZT (ref TDF)	0.86	0.67	1.10
ART Core Drug: PI (ref NNRTI)	0.91	0.70	1.18
ART Core Drug: INSTI	7.12	2.97	17.09
Baseline Diagnosis of Hypertension	1.54	1.09	2.16
Baseline Diagnosis of Diabetes Mellitus	1.92	1.09	3.36



Disclosures. All authors: No reported disclosures.

1685. Predictors of Linkage to and Retention in HIV Care Following Release from Connecticut Jails and Prisons

Kelsey B. Loeliger, MPhil, BS¹; Frederick L. Altice, MD^{2,3}; Mayur M. Desai, PhD, MPH⁴; Maria M. Ciarleglio, PhD⁵; Colleen Gallagher, CADAC, CCHP⁶; Jaimie P. Meyer, MD, MS⁷; ¹Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, Connecticut; ²Yale University School of Medicine, Yale School of Public Health; ³Yale University AIDS Program, Yale Clinical and Community Research, Yale Center for Interdisciplinary Research on AIDS, New Haven, Connecticut; ⁴Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut; ⁵Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut; ⁶Quality Improvement Health and Addiction Services, Connecticut Department of Correction, Wethersfield, Connecticut; ⁷Medicine, Yale University, New Haven, Connecticut

Session: 188. HIV: Modern ART
Friday, October 6, 2017: 2:00 PM

Background. One in six people living with HIV (PLH) in the USA transition through prison or jail annually. During incarceration, people may engage in HIV care, but transition to the community remains challenging. Linkage to care (LTC) post-release and retention in care (RIC) are necessary to optimizing HIV outcomes, but have been incompletely assessed in prior observational studies.

Methods. We created a retrospective cohort of all PLH released from a Connecticut jail or prison (2007–2014) by linking Department of Correction demographic, pharmacy, and custody databases with Department of Public Health HIV surveillance monitoring and case management data. We assessed time to LTC, defined as time from release to first community HIV-1 RNA test, and viral suppression status at time of linkage. We used generalized estimating equations to identify correlates of LTC within 14 or 30 days after release. We also described RIC over three years following an initial release, comparing recidivists to non-recidivists.

Results. Among 3,302 incarceration periods from 1,350 unique PLH, 21% and 34% had LTC within 14 and 30 days, respectively, of which >25% had detectable viremia at time of linkage. Independent correlates of LTC at 14 days included incarceration periods >30 days (adjusted odds ratio [AOR] = 1.6; $P < 0.001$), higher medical comorbidity (AOR = 1.8; $P < 0.001$), antiretrovirals prescribed before release (AOR = 1.5; $P = 0.001$), transitional case management (AOR = 1.5; $P < 0.001$), re-incarceration (AOR = 0.7; $P = 0.002$) and conditional release (AOR = 0.6; $P < 0.001$). The 30-day model additionally included psychiatric comorbidity (AOR = 1.3; $P = 0.016$) and release on bond (AOR = 0.7; $P = 0.033$). Among 1,094 PLH eligible for 3-year follow-up, RIC after release declined over 1 year (67%), 2 years (51%) and 3 years (42%). Recidivists were more likely than nonrecidivists to have RIC but, among those retained, were less likely to be virally suppressed (Figure 1).

Conclusion. For incarcerated PLH, both LTC and RIC as well as viral suppression are suboptimal after release. PLH who receive case management are more likely to have timely LTC. Targeted interventions and integrated programming aligning health and criminal justice goals may improve post-release HIV treatment outcomes.




Figure 1. Longitudinal sustained retention in HIV care at one, two, and three years post-release, based on frequency of HIV-1 RNA viral testing, stratified by whether individuals were re-incarcerated at some point during the follow-up period. *statistically significant decline (McNemar's test $p < 0.0001$) compared with initial one-year rates. **statistically significant decline (McNemar's test $p < 0.0001$) compared with sustained two-year rates. *statistically significant difference ($\chi^2 p < 0.0001$) in retention rates between recidivists and non-recidivists across all time points. Among those retained, non-recidivists had higher viral suppression rates compared to recidivists at end of year 1 ($p = 0.021$) and year 3 ($p = 0.048$).

Disclosures. All authors: No reported disclosures.

1686. Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

Brinda Emu, MD¹; W Jeffrey Fessel, MD²; Shannon Schrader, MD³; Princy N. Kumar, MD, FIDSA⁴; Gary Richmond, MD⁵; Sandra Win, MD, MS⁶; Steven Weinheimer, PhD⁷; Christian Marsolais, PhD⁸; Stanley Lewis, MD⁷; ¹Yale School of Medicine, New Haven, Connecticut; ²Kaiser Foundation Research Institute, San Francisco, California; ³Research Access Network, Houston, Texas; ⁴Georgetown University Medical Center, Washington, District of Columbia; ⁵Gary Richmond, Pennsylvania, Fort Lauderdale, Florida; ⁶eStudy Site, San Francisco, California; ⁷TaiMed Biologics USA, Irvine, California; ⁸Medical Affairs, Theratechnologies Inc., Montreal, QC, Canada

Session: 188. HIV: Modern ART
Friday, October 6, 2017: 2:00 PM

Background. Management of multi-drug-resistant (MDR) HIV-1 remains a challenge. The advent of antiretroviral (ARV) with novel mechanisms of action are needed to expand therapeutic options for MDR patients. Ibalizumab (IBA) is a humanized monoclonal antibody with a unique binding specificity to the CD4 domain 2, allowing it to block viral entry into host cells without CD4 depletion. Patients completing the 24-week Phase 3 study (TMB-301) continued treatment in study TMB-311. Here, we report the durable efficacy and long-term safety of IBA with an optimized background regimen (OBR) through 48 weeks of treatment.

Methods. TMB-301 was an open-label study investigating the antiviral activity and safety of IBA plus OBR in highly treatment-experienced patients with MDR HIV-1. Patients received an intravenous loading dose of 2,000 mg followed by 800 mg doses every 2 weeks for 24 weeks. 7 days after loading dose, an OBR was added with at least 1 additional sensitive agent throughout the study. Following completion of the 24-week TMB-301 study, patients continued to receive IBA at 800 mg every 2 weeks under TMB-311 for up to 48 weeks. Safety and efficacy were assessed until 48 weeks.

Results. A total of 31 patients enrolled in TMB-301 completed the 24-week treatment period. Of 31 patients, 27 entered study TMB-311. These patients were highly resistant patients - 59% and 33% of patients had exhausted ≥ 3 and ≥ 4 ARV classes, respectively; and 7% of patients had HIV-1 resistant to all approved ARVs. IBA plus OBR was well tolerated. Of the 27 patients, 24 (89%) continued to receive treatment until Week 48. The three patients discontinued early due to non IBA-related reasons. No new or unexpected safety concerns emerged between Week 24 and 48. The potent suppression of viremia observed Week 24 was sustained through Week 48. Median viral load (VL) reduction from BL was 2.5 log₁₀ at both Week 24 and 48. Of 27 patients (59%) 16 had VL <50 copies/ml and 17 (63%) patients had VL < 200 copies/ml. All 15 patients with VL < 50 copies/ml at Week 24 maintained viral suppression to Week 48.

Conclusion. IBA plus OBR continued to achieve high rates of virologic suppression through Week 48. The results support the durable efficacy and long-term safety